Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Annals of Neurology
|
January 1, 1989
The prevalence of primary Sjögren's syndrome in a multiple sclerosis population
J H Noseworthy, B H Bass, M K Vandervoort, et al.
Alimentary Pharmacology & Therapeutics
|
September 22, 2015
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
V Jairath, R Khanna, G Y Zou, et al.
Annals of Neurology
|
November 1, 1992
Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis
S Wiebe, D H Lee, S J Karlik, et al.
Alimentary Pharmacology & Therapeutics
|
October 29, 2014
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
R Khanna, G Zou, G D'Haens, et al.
Neurology
|
July 1, 1993
An open-trial evaluation of mitoxantrone in the treatment of progressive MS
J H Noseworthy, M B Hopkins, M K Vandervoort, et al.
Alimentary Pharmacology & Therapeutics
|
June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's disease
M A Samaan, C A J Puylaert, B G Levesque, et al.
Alimentary Pharmacology & Therapeutics
|
June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
G R D'Haens, W J Sandborn, G Zou, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Annals of Neurology
|
January 1, 1989
The prevalence of primary Sjögren's syndrome in a multiple sclerosis population
J H Noseworthy, B H Bass, M K Vandervoort, et al.
Alimentary Pharmacology & Therapeutics
|
September 22, 2015
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
V Jairath, R Khanna, G Y Zou, et al.
Annals of Neurology
|
November 1, 1992
Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis
S Wiebe, D H Lee, S J Karlik, et al.
Alimentary Pharmacology & Therapeutics
|
October 29, 2014
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
R Khanna, G Zou, G D'Haens, et al.
Neurology
|
July 1, 1993
An open-trial evaluation of mitoxantrone in the treatment of progressive MS
J H Noseworthy, M B Hopkins, M K Vandervoort, et al.
Alimentary Pharmacology & Therapeutics
|
June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's disease
M A Samaan, C A J Puylaert, B G Levesque, et al.
Alimentary Pharmacology & Therapeutics
|
June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis
G R D'Haens, W J Sandborn, G Zou, et al.
Page
of 2